



MDR-TB

PCR/Mycobacteria

FluoroType[®] MTBDR VER 2.0

Detect multidrug-resistant tuberculosis

Innovation with Integrity

Detect TB and report resistance to rifampicin and isoniazid from one WHO-endorsed test

- Detect *Mycobacterium tuberculosis* complex and resistances to rifampicin and isoniazid in one PCR well
- Report specific resistance-mediating mutations for individualized treatment and for disease surveillance
- Comprehensive portfolio covers: TB, first- and second-line resistances, and nontuberculous mycobacteria
- Reuse the DNA extract with validated assays and run all LiquidArray[®] mycobacteria assays on the same PCR plate

Powered by
LiquidArray[®]

IVD

FluoroType® MTBDR VER 2.0 for detecting TB and resistances to rifampicin and isoniazid

Tuberculosis (TB) affects over 10 million people worldwide, with an estimated one in eight cases resistant to the most important first-line antibiotics – rifampicin (RIF), isoniazid (INH), or both. Failure to recognise drug-resistant infection early on leads to inadequate treatment and fuels emergence of multidrug-resistant strains.

Rapid and reliable detection of resistance-mediating mutations is essential for fast intervention and effective disease management at individual and public health levels.

- Detect *M. tuberculosis* complex with high specificity and sensitivity
- Identify resistances to two most important first-line drugs (RIF/INH)
- Differentiate up to 45 mutations in resistance-mediating genes in one well
- From sample to sequencing-like results in under 5 hours (up to 94 samples)

Sample	Extraction and PCR setup	Targets	45 mutations in genes mediating resistances to
Decontaminated sputum Culture Native sputum*	Manual (1-94 samples): FluoroLyse Automated extraction (1-12 samples): GenoXtract® X2 cartridge Automated extraction & PCR setup (12-94 samples): GenoXtract® fleXT GXT96 X2 extraction kit	<i>IS6110*</i> <i>rpoB</i> <i>katG</i> <i>inhA</i>	√ Rifampicin √ Isoniazid
*coming 2024		*coming 2024	

Same DNA extract can be re-used in all validated LiquidArray® mycobacteria assays

Powered by LiquidArray®

FluoroType® MTBDR VER 2.0 is a multiplex assay for detection of *M. tuberculosis* complex and up to 45 mutations in genes mediating resistances to rifampicin and isoniazid in one PCR well. The test is validated for decontaminated sputum or culture specimens. Workflows supporting any testing demand from 1-94 samples per run are available from manual to automated DNA extraction and PCR setup. Amplification and detection are performed in the FluoroCycler® XT. Users benefit from receiving results at a glance with individual mutations and resistance interpretation displayed in a clear, colour-coded report.

FluoroType® MTBDR VER 2.0 is complemented by LiquidArray® MTB-XDR VER 1.0, which reports additional resistances to fluoroquinolones, linezolid, amikacin and ethambutol. Together with FluoroType® Mycobacteria VER 1.0 assay, which detects up to 32 clinically relevant NTM species, the three assays form a core comprehensive molecular diagnostic workflow, essential for every mycobacteria laboratory.

Order information



FluoroType® MTBDR VER 2.0
Part No. H-62896
96 tests / 85 tests (GenoXtract® fleXT)

Please contact your local representative for availability in your country.
Not for sale in the USA.

LiquidArray®, FluoroCycler®, GenoXtract® and FluoroSoftware® are registered trademarks of the Bruker group of companies.
GenoXtract® fleXT Hamilton Bonaduz AG, Via Crusch 8, CH-7402 Bonaduz, Switzerland

Hain Lifescience GmbH

Nehren · Germany
Phone +49 (0) 7473-9451-0

info.mdx.de@bruker.com
hain-lifescience.de

Online information
bruker.com/microbiology

